Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Q3 beat with raised guidance and multiple analyst target hikes support near-term positive momentum, tempered by an 8-K correcting an ASH abstract and the upcoming December ASH data readout as the key binary catalyst.
Schrödinger reported Q3 2026 total revenue of $64.5M (+19% YoY), ACV of $44.7M (+17%), and drug discovery revenue of $24.2M, then raised FY2026 ACV guidance to $222–232M and drug discovery revenue to $75–85M. The beat-and-raise supports positive near-term sentiment and underpins analyst target increases.
Schrödinger Press ReleaseTD Cowen maintained Buy and lifted its price target to $36 from $31, while the average 12-month target rose to $29 from $25.86 with a Buy consensus (five Buy, two Hold). Upward estimate/target revisions following the Q3 beat can drive near-term buying interest.
TradingView NewsSchrödinger amended its Novartis collaboration, replacing programs and increasing potential milestone payments to $1.424B; Bristol Myers Squibb also adopted its Bunsen platform. Expanded partnership economics reinforce the platform's commercial validation and support sentiment.
TradingView NewsSchrödinger filed an 8-K correcting its ASH abstract, clarifying it has not initiated a combination study of SGR-1505 under its FDA-cleared protocol and is exploring strategic opportunities to continue development. The correction could temper expectations around the MALT1 program ahead of the December data readout.
SEC Filing (8-K)Updated Phase 1 data for zilemaltib (SGR-1505) in relapsed/refractory B-cell malignancies will be presented in an oral session at the ASH Annual Meeting (Dec 12–15, 2026), with dose escalation complete. This is a near-term binary catalyst that could move shares depending on safety/efficacy results.
Schrödinger Press Release